Trial Profile
An Open Label, Multi-part drug-drug interaction study to evaluate the effects of rolapitant on the Pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2019
Price :
$35
*
At a glance
- Drugs Rolapitant (Primary) ; Dextromethorphan; Efavirenz; Omeprazole; Repaglinide; Tolbutamide
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Pharmacokinetics
- 01 Mar 2019 Results published in the Supportive Care in Cancer
- 09 Jun 2016 New trial record